RSV is the leading viral agent causing severe respiratory tract disease worldwide in older adults. There are currently no vaccines available in Australia for the prevention of RSV in older adults.
Therefore, there is an unmet medical need to address the prevention of respiratory disease in older adults while improving quality of life. The investigational vaccine that will be evaluated in this study is an mRNA vaccine.
Participation in this study will last around 12 months (if you only receive 1 study vaccination) or around 24 months (if you are eligible for a booster vaccination). It will include around 8 in-clinic visits and 4 phone visits if you are in the group that only receives 1 study vaccination, and an additional 7 visits and 4 phone visits if you are in the group that is eligible for a booster vaccination. You will also receive occasional contact with the study team (e.g., phone calls, text messages and emails). Taking part in this study is voluntary and you may leave at any time for any reason.
Among other things, participants must:
Please visit https://www.griffith.edu.au/griffith-health/clinical-trial-unit/current-trials or email the study team at firstname.lastname@example.org for more information.
Register your interest here